| scholarly article | Q13442814 |
| P2093 | author name string | Philip McFarlane | |
| Paul Komenda | |||
| Daniel G Bichet | |||
| Steven Soroka | |||
| Louis-Philippe Girard | |||
| Paul Tam | |||
| Ahsan Alam | |||
| Sanjaya Pandeya | |||
| Rolf Loertscher | |||
| Micheli Bevilacqua | |||
| P2860 | cites work | Autosomal dominant polycystic kidney disease: the last 3 years | Q24656249 |
| Evidence-based clinical practice guidelines for polycystic kidney disease 2014 | Q26752272 | ||
| Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice | Q26767011 | ||
| Current management of autosomal dominant polycystic kidney disease | Q26784073 | ||
| PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein | Q28280639 | ||
| Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease | Q33571813 | ||
| Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. | Q33762978 | ||
| Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group | Q33852423 | ||
| Temporal and geographical external validation study and extension of the Mayo Clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients. | Q33910788 | ||
| Renal function and healthcare costs in patients with polycystic kidney disease | Q34075500 | ||
| Molecular diagnostics for autosomal dominant polycystic kidney disease | Q34100184 | ||
| Genetics and pathogenesis of polycystic kidney disease. | Q34145624 | ||
| Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells | Q34343042 | ||
| Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials | Q34423262 | ||
| Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease | Q34529587 | ||
| Angiotensin blockade in late autosomal dominant polycystic kidney disease | Q34836649 | ||
| Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. | Q34858052 | ||
| Blood pressure in early autosomal dominant polycystic kidney disease | Q35129320 | ||
| Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. | Q35827271 | ||
| Evaluation of urine biomarkers of kidney injury in polycystic kidney disease | Q35870104 | ||
| Automatic total kidney volume measurement on follow-up magnetic resonance images to facilitate monitoring of autosomal dominant polycystic kidney disease progression | Q36497881 | ||
| Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort | Q36616057 | ||
| The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease. | Q36624712 | ||
| Autosomal dominant polycystic kidney disease: role of the renin-angiotensin system in raised blood pressure in progression of renal and cardiovascular disease | Q36648822 | ||
| Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease | Q36741005 | ||
| Automated Segmentation of Kidneys from MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease | Q36770909 | ||
| Type of PKD1 mutation influences renal outcome in ADPKD. | Q36880400 | ||
| Diagnostic approach in autosomal dominant polycystic kidney disease | Q36910487 | ||
| What is next generation sequencing? | Q37346079 | ||
| Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study | Q37620079 | ||
| Imaging for the prognosis of autosomal dominant polycystic kidney disease | Q37683368 | ||
| Diagnosis of autosomal-dominant polycystic kidney disease: an integrated approach | Q37784293 | ||
| Molecular diagnosis of autosomal dominant polycystic kidney disease | Q37832661 | ||
| Genetics and pathogenesis of autosomal dominant polycystic kidney disease: 20 years on. | Q38255110 | ||
| Volumetric determination of progression in autosomal dominant polycystic kidney disease by computed tomography | Q38463067 | ||
| Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study. | Q38848641 | ||
| Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial | Q38853071 | ||
| Prevalence of autosomal dominant polycystic kidney disease in the European Union | Q38871411 | ||
| Polycystic Kidney Disease without an Apparent Family History | Q40195826 | ||
| Estimation of total kidney volume in autosomal dominant polycystic kidney disease | Q40667713 | ||
| Unified criteria for ultrasonographic diagnosis of ADPKD. | Q41829694 | ||
| Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease | Q42927109 | ||
| Family history of renal disease severity predicts the mutated gene in ADPKD. | Q43074229 | ||
| Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort | Q44545045 | ||
| Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial | Q46081472 | ||
| Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease | Q46220838 | ||
| Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4. | Q47110579 | ||
| Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease | Q47666190 | ||
| Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. | Q47907872 | ||
| Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial | Q47925751 | ||
| The prevalence of autosomal dominant polycystic kidney disease (ADPKD): A meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition | Q48235375 | ||
| New treatment paradigms for ADPKD: moving towards precision medicine | Q49494721 | ||
| Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials | Q49855458 | ||
| Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease | Q50143661 | ||
| Low-Osmolar Diet and Adjusted Water Intake for Vasopressin Reduction in Autosomal Dominant Polycystic Kidney Disease: A Pilot Randomized Controlled Trial | Q50350995 | ||
| Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. | Q51001591 | ||
| Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. | Q51735152 | ||
| A Patient with a Novel Gene Mutation Leading to Autosomal Dominant Polycystic Kidney Disease. | Q53122013 | ||
| Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP) | Q81536225 | ||
| Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children | Q88581728 | ||
| Volume progression in polycystic kidney disease | Q94478608 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | autosomal dominant polycystic kidney disease | Q15443105 |
| autosomal dominant polycystic kidney | Q2732398 | ||
| pharmacology | Q128406 | ||
| P304 | page(s) | 2054358118801589 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | Canadian journal of kidney health and disease | Q27726098 |
| P1476 | title | Updated Canadian Expert Consensus on Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease | |
| P478 | volume | 5 |
| Q92019794 | Autosomal dominant polycystic kidney disease |
| Q92128969 | Dietary Care for ADPKD Patients: Current Status and Future Directions |
| Q89486498 | Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention |
Search more.